

IN THE ABSTRACT

No changes.

IN THE DISCLOSURE

No changes.

IN THE CLAIMS

Applicant respectfully requests the following amendments be made to the claims and the following new claims be added. These claims were added to insert claims corresponding to those for which the Examiner raised objections under 35 U.S.C. 112 on account of multiple dependency. No new subject matter has been added to the application.

*Sub E1* 1. (Amended) A controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a C<sub>max</sub> of Diltiazem in the blood at between about 10 hours and about 15 hours (T<sub>max</sub>) after administration of the preparation, the preparation being in a sustained-release dosage form in which the form of Diltiazem is adapted to be control released after administration of the preparation over a period of time and being adapted to release the form of Diltiazem

(i) into an aqueous medium at the following rates measured using the method of United States Pharmacopoeia No. XXIII at 100 rpm in 900 ml of water:

(a) between about 1% and about 15% after 2 hours;

- (b) between about 7% and about 35% after 4 hours;
- (c) between about 30% and about 58% after 8 hours;
- (d) between about 55% and about 80% after 14 hours; and
- (e) and in excess of about 75% after 24 hours.

and/or (ii) into a buffered medium having a pH between about 5.5 and about 6.5, at the following rates measured using the method of United States Pharmacopoeia No. XXIII at 100 rpm in 900ml of the buffered medium:

- (a) between about 1% and about 25% after about 2 hours;
- (b) between about 7% and about 45% after about 4 hours;
- (c) between about 30% and about 68% after about 8 hours;
- (d) in excess of about 75% after about 24 hours.

2. (Amended) A controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 15 hours (Tmax) after administration, the preparation being in a sustained-release dosage form in which the form of Diltiazem is adapted to be control released after administration of the preparation over a period of time and being adapted to release the form of Diltiazem

(i) into an aqueous medium at the following rates measured using the method of United States Pharmacopoeia No. XXIII at 100 rpm in 900 ml of water:

- (a) between about 4% and about 8% after 2 hours;
- (b) between about 16% and about 21% after 4 hours;
- (c) between about 44% and about 52% after 8 hours;
- (d) between about 69% and about 76% after 14 hours; and
- (e) and in excess of about 85% after 24 hours;

and/or (ii) into a buffered medium having a pH about 5.8 at the following rates measured using the method of United States Pharmacopoeia No. XXIII at 100 rpm in 900ml of the buffered medium:

- (a) between about 4% and about 15% after 2 hours;
- (b) between about 16% and about 30% after 4 hours;
- (c) between about 44% and about 62% after 8 hours;
- (d) in excess of about 80% after 24 hours.

4. (Twice Amended) The preparation of claim [1 or] 2 wherein the [Diltiazem is in the form of Diltiazem HCl] C<sub>max</sub> of Diltiazem in the blood is obtained between about 11 - about 13 hours after administration of the preparation.

5. (Twice Amended) The preparation of claim [1 or 2] 1, 2, 3 or 4 wherein the preparation is a diffusion controlled preparation.

6. (Twice Amended) The preparation of claim [1 or 2] 1, 2, 3, or 4 wherein the preparation releases the form of Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution.

7. (Twice Amended) The preparation of claim [1 or 2] 1, 2, 3, or 4 wherein the preparation is in capsule form.

8. (Twice Amended) The preparation of claim [1 or 2] 1, 2, 3, or 4 wherein the preparation is in tablet form.

D3 Cmt  
9. (Thrice Amended) The preparation of claim [1 or 2] 1, 2, 3, or 4 wherein the preparation comprises a plurality of microgranules, [wherein] each microgranule [comprises] comprising a central core containing [of] the form of diltiazem coated with a microporous membrane and the central core comprises the form of Diltiazem or [a] pharmaceutically acceptable salt thereof associated with a wetting agent[, wherein the central core is coated with a microporous membrane].

---

D4  
10. (Amended) The preparation of claim [9] 1, 2, 3 or 4 wherein the preparation comprises a plurality of microgranules, each microgranule comprising a central core containing the form of Diltiazem coated with a microporous membrane and the central core comprises the form of Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the form of Diltiazem is mixed [(in whole or in part)] with the wetting agent.

---

D5  
11. (Twice Amended) The preparation of claim [10] 1, 2, 3 or 4 wherein the preparation comprises a plurality of microgranules, each microgranule comprising a central core containing the form of Diltiazem coated with a microporous membrane and the central core comprises the form of Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the form of Diltiazem is mixed with the wetting agent wherein the wetting agent assists to maintain the solubility of the form of Diltiazem in each [microgranule] bead, ensuring that the solubility of the form of Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein.

D6 12. (Thrice Amended) The preparation of claim [9] 1, 2, 3 or 4 wherein the preparation comprises a plurality of microgranules, each microgranule comprising a central core containing the form of Diltiazem coated with a microporous membrane and the central core comprises the form of Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation.

D7 13. (Twice Amended) The preparation of claim [9] 1, 2, 3 or 4 wherein the preparation comprises a plurality of microgranules, each microgranule comprising a central core containing the form of Diltiazem coated with a microporous membrane and the central core comprises the form of Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent wherein the preparation comprises a mixture of the form of Diltiazem and/or pharmaceutically acceptable salt with the wetting agent and the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation.

D8 14. (Thrice Amended) The preparation of claim [9] 1, 2, 3 or 4 wherein the preparation comprises a plurality of microgranules, each microgranule comprising a central core containing the form of Diltiazem coated with a microporous membrane and the central core comprises the form of Diltiazem or pharmaceutically acceptable

DS  
cm  
salt thereof associated with a wetting agent wherein the membrane comprises a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester and hydroxypropylmethylcellulose.

15. (Twice Amended) The preparation of claim [14] 1, 2, 3 or 4 wherein the preparation comprises a plurality of microgranules, each microgranule comprising a central core containing the form of Diltiazem coated with a microporous membrane and the central core comprises the form of Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent, and wherein the membrane hydrates the core within [a] the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the [microgranule] bead, and dissolves the form of diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside).

16. (Twice Amended) The preparation of claim [10 or 11] 9 wherein the form of Diltiazem is mixed with the wetting agent and the membrane comprises N,N,N-trimethyl-2-[(2-methyl-1-oxo-2-propenyl)oxy]-chloride ethanaminium polymer with ethyl-2-propenoate and methyl-2-methyl-2-propenoate, an acrylic polymer [Eudragit RS, Eudragit RL] and plasticizer combined to form the membrane thereby providing a mechanism of release from this membrane which "washes" the form of diltiazem through pores created when the plasticizer incorporated in the membrane, is released in gastrointestinal fluid.

D9  
~~17~~  
Cmt

17. (Twice Amended) The preparation of claim 1, 2, 3, or 4 wherein the preparation comprises a plurality of microgranules comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises the form of Diltiazem or a pharmaceutically acceptable salt thereof associated with a [any suitable] dissolution agent (other than a wetting agent) to assist in the release of the form of Diltiazem from the preparation.

---

D10  
sub  
E2

18. (Thrice Amended) The preparation of claim [2] 1, 2, 3 or 4 wherein the preparation comprises a plurality of microgranules comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or a pharmaceutically acceptable salt thereof associated with [any suitable] a dissolution agent (other than a wetting agent) to assist in the release of the form of Diltiazem from the preparation and wherein [the preparation comprises a plurality of microgranules comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or a pharmaceutically acceptable salt thereof associated with any suitable dissolution agent (other than a wetting agent) to assist in the release of the Diltiazem from the preparation and wherein] the dissolution agent is an organic acid selected from the group consisting of adipic acid, ascorbic acid, citric acid, fumaric acid, malic acid, succinic acid, [and] tartaric acid and the like which permits the form of diltiazem to dissolve in gastrointestinal fluids when the microgranules pass into the higher pH regions of the gastrointestinal tract of the intestine at which pH diltiazem is much less soluble.

---

DI 19. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 1 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

20. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 2 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

21. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 3 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

22. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 4 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

23. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 5 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

24. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 6 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.



25. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 7 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

D11  
Cmt  
26. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 8 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

27. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 9 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

28. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 10 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

29. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 11 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

30. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 12 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

31. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 13 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

32. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 14 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

33. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 15 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

34. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 16 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

35. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 17 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

36. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 18 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

D12 37. (Twice Amended) The preparation of claim 1, 2, 3, or 4 wherein the preparation contains 120 mg of Diltiazem.

38. (Twice Amended) The preparation of claim 1, 2, 3, or 4 wherein the preparation contains 180 mg of Diltiazem.

39. (Twice Amended) The preparation of claim 1, 2, 3, or 4 wherein the preparation contains 240 mg of Diltiazem.

40. (Twice Amended) The preparation of claim 1, 2, 3, or 4 wherein the preparation contains 300 mg of Diltiazem.

41. (Twice Amended) The preparation of claim 1, 2, 3, or 4 wherein the preparation contains 360 mg of Diltiazem.

42. (Twice Amended) The preparation of claim 1, 2, 3, or 4 wherein the preparation contains 420 mg of Diltiazem.

D13 43. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 37, 38, 39, 40, 41 or 42 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

44. (Amended) A controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts

thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a C<sub>max</sub> of Diltiazem in the blood at between about 10 hours and about 15 hours (T<sub>max</sub>) after administration of the preparation, the preparation being in a sustained-release dosage form in which the form of Diltiazem is adapted to be control released after administration of the preparation over a period of time and being adapted to release the Diltiazem

(i) into an aqueous medium at the following rates measured using the method of United States Pharmacopoeia No. XXIII at 100 rpm in 900 ml of water:

- (a) between about 1% and about 15% after 2 hours;
- (b) between about 7% and about 35% after 4 hours;
- (c) between about 30% and about 58% after 8 hours;
- (d) between about 55% and about 80% after 14 hours; and
- (e) and in excess of about 75% after 24 hours.

and/or (ii) into a buffered medium having a pH between about 5.5 and about 6.5, at the following rates measured using the method of United States Pharmacopoeia No. XXIII at 100 rpm in 900ml of the buffered medium:

- (a) between about 1% and about 25% after about 2 hours;
- (b) between about 7% and about 45% after about 4 hours;
- (c) between about 30% and about 68% after about 8 hours;
- (d) in excess of about 75% after about 24 hours wherein the preparation comprises a plurality of microgranules, wherein each microgranule comprises a central core of the form of diltiazem or a pharmaceutically acceptable salt thereof, associated with a wetting agent, wherein the central core is coated with a microporous membrane and wherein the wetting agent is selected from the group consisting of:

sugars;

saccharose, mannitol, sorbitol;

lecithins;

C<sub>12</sub> to C<sub>20</sub> fatty acid esters of saccharose;;

xylose esters or xylites;

polyoxyethylenic glycerides;

esters of fatty acids and polyoxyethylene;

sorbitan fatty acid esters;

polyglycides-glycerides and polyglycides-alcohols esters and

Metal salts.

46. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 44 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

47. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 3 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning wherein each microgranule comprises a central core of the form of diltiazem or a pharmaceutically acceptable salt thereof, associated with a wetting agent, wherein the central core is coated with a microporous membrane and wherein the wetting agent is in association with the diltiazem in the microgranule and not mixed therewith, the membrane comprises a water-soluble or water dispersible polymer or copolymer and a water-, acid- and base-insoluble polymer which is a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester enabling the bead to be hydrated by the introduction of intestinal fluids into the core hydrating the core and therefore mixing the diltiazem and the wetting agent.

48. (Amended) A controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts

thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 15 hours (Tmax) after administration of the preparation, the preparation being in a sustained-release dosage form in which the Diltiazem is adapted to be control released after administration of the preparation over a period of time and being adapted to release the Diltiazem

(i) into an aqueous medium at the following rates measured using the method of United States Pharmacopoeia No. XXIII at 100 rpm in 900 ml of water:

- (a) between about 1% and about 15% after 2 hours;
- (b) between about 7% and about 35% after 4 hours;
- (c) between about 30% and about 58% after 8 hours;
- (d) between about 55% and about 80% after 14 hours; and
- (e) and in excess of about 75% after 24 hours.

and/or (ii) into a buffered medium having a pH between about 5.5 and about 6.5, at the following rates measured using the method of United States Pharmacopoeia No. XXIII at 100 rpm in 900ml of the buffered medium:

- (a) between about 1% and about 25% after about 2 hours;
- (b) between about 7% and about 45% after about 4 hours;
- (c) between about 30% and about 68% after about 8 hours;
- (d) in excess of about 75% after about 24 hours, wherein the

preparation comprises a plurality of microgranules, wherein each microgranule comprises a central core of the form of diltiazem or a pharmaceutically acceptable salt thereof, associated with a wetting agent, wherein the central core is coated with a microporous membrane in which the core and membrane comprise:

	% W/W
(a) Diltiazem hydrochloride	69 - 73

(b)	Microcrystalline cellulose	8 - 9.5
(c)	Povidone K30	1 - 2
(d)	Sucrose stearate	7 - 8
(e)	Magnesium stearate NF	0.5 - 2.5
(f)	Talc USP	0.5 - 5.0
(g)	Titanium dioxide (USP)	0.15 - 0.3
(h)	Hydroxypropylmethylcellulose 2910	0.3 - 0.6
(i)	Polysorbate 80 (tween)	0.01 - 0.025
(j)	Simeticone C emulsion USP (dry of 30%)	0.01 - 0.015
(k)	a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester (dry of 30%)	7 - 11
	Purified water USP	0 (used for mixing).

49. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 48 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

50. (Amended) A controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 15 hours (Tmax) after administration of the preparation, the preparation being in a sustained-release dosage form in which the Diltiazem is adapted to be control released after administration of the preparation over a period of time and being adapted to release the Diltiazem

(i) into an aqueous medium at the following rates measured using the method of United States Pharmacopoeia No. XXIII at 100 rpm in 900 ml of water:

- D4  
cont
- (a) between about 1% and about 15% after 2 hours;
  - (b) between about 7% and about 35% after 4 hours;
  - (c) between about 30% and about 58% after 8 hours;
  - (d) between about 55% and about 80% after 14 hours; and
  - (e) and in excess of about 75% after 24 hours.

Cont  
E5

and/or (ii) into a buffered medium having a pH between about 5.5 and about 6.5, at the following rates measured using the method of United States Pharmacopoeia No. XXIII at 100 rpm in 900ml of the buffered medium:

- (a) between about 1% and about 25% after about 2 hours;
- (b) between about 7% and about 45% after about 4 hours;
- (c) between about 30% and about 68% after about 8 hours;
- (d) in excess of about 75% after about 24 hours, wherein the

preparation comprises a plurality of microgranules, wherein each microgranule comprises a central core of the form of diltiazem or a pharmaceutically acceptable salt thereof, associated with a wetting agent, wherein the central core is coated with a microporous membrane in which the core and membrane comprise:

(i) in the core,

(a) between about 50% and about 85% (% w/w of the total preparation) of Diltiazem or pharmaceutically acceptable salt thereof; and

(b) between about 2% and about 25% wetting agent (% w/w of the total preparation);

together with suitable adjuvants; and

(ii) in the membrane,



Cont  
E5

(c) between about 0.1% and about 2% of the total preparation of water-soluble and/or water-dispersible polymer; and

D14  
cont

(d) between about 5% and about 20% (% w/w of the preparation) of a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester, together with suitable adjuvants.

51. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 50 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

52. (Amended) A controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a C<sub>max</sub> of Diltiazem in the blood at between about 10 hours and about 15 hours (T<sub>max</sub>) after administration of the preparation, the preparation being in a sustained-release dosage form in which the Diltiazem is adapted to be control released after administration of the preparation over a period of time and being adapted to release the Diltiazem

(i) into an aqueous medium at the following rates measured using the method of United States Pharmacopoeia No. XXIII at 100 rpm in 900 ml of water:

- (a) between about 1% and about 15% after 2 hours;
- (b) between about 7% and about 35% after 4 hours;
- (c) between about 30% and about 58% after 8 hours;
- (d) between about 55% and about 80% after 14 hours; and
- (e) and in excess of about 75% after 24 hours.

and/or (ii) into a buffered medium having a pH between about 5.5 and about 6.5, at the following rates measured using the method of United States Pharmacopoeia No. XXIII at 100 rpm in 900ml of the buffered medium:

- (a) between about 1% and about 25% after about 2 hours;
- (b) between about 7% and about 45% after about 4 hours;
- (c) between about 30% and about 68% after about 8 hours;
- (d) in excess of about 75% after about 24 hours, wherein the

preparation comprises a plurality of microgranules, wherein each microgranule comprises a central core of the form of diltiazem or a pharmaceutically acceptable salt thereof, associated with a wetting agent, wherein the central core is coated with a microporous membrane in which the core and membrane comprise:

(i) in the core,

- (a) between about 69% and about 73% (% w/w of the total preparation) of Diltiazem or pharmaceutically acceptable salt thereof; and
- (b) between about 7% and about 8% wetting agent (% w/w of the total preparation);

together with suitable adjuvants; and

(ii) in the membrane,

- (c) between about 0.3% and about 0.6% of the total preparation of water-soluble and/or water-dispersible polymer; and
- (d) between about 7% and about 11% (% w/w of the preparation) of a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester, together with suitable adjuvants.

D14  
Cmt

53. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 52 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

---

D15

55. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 54 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

---

56. (Amended) A controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a C<sub>max</sub> of Diltiazem in the blood at between about 10 hours and about 15 hours (T<sub>max</sub>) after administration of the preparation, the preparation being in a sustained-release dosage form in which the Diltiazem is adapted to be control released after administration of the preparation over a period of time wherein the preparation comprises a plurality of microgranules, each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent in which the core and membrane comprise:

(i) in the core,

(a) between about 50% and about 85% (% w/w of the total preparation) of Diltiazem or pharmaceutically acceptable salt thereof; and

(b) between about 2% and about 25% wetting agent (% w/w of the total preparation);

DIS  
cont  
together with suitable adjuvants; and

(ii) in the membrane,

Cont  
ES  
(c) between about 0.1% and about 2% of the total preparation of water-soluble and/or water-dispersible polymer; and

(d) between about 5% and about 20% (% w/w of the preparation) of a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester, together with suitable adjuvants.

DIS  
SUB  
E10  
60. (Amended) A controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a C<sub>max</sub> of Diltiazem in the blood at between about 10 hours and about 15 hours (T<sub>max</sub>) after administration of the preparation, the preparation being in a sustained-release dosage form in which the Diltiazem is adapted to be control released after administration of the preparation over a period of time wherein the preparation comprises a plurality of microgranules, each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent in which the core and membrane comprise:

(i) in the core,

(a) between about 50% and about 85% (% w/w of the total preparation) of Diltiazem or pharmaceutically acceptable salt thereof; and

(b) between about 2% and about 25% wetting agent (% w/w of the total preparation);

together with suitable adjuvants; and

(ii) in the membrane,

(c) between about 0.1% and about 2% of the total preparation of water-soluble and/or water-dispersible polymer; and

(d) between about 5% and about 20% (% w/w of the preparation) of a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester, together with suitable adjuvants wherein the core and membrane comprise:

	% W/W
(a) Diltiazem hydrochloride	69 - 73
(b) Microcrystalline cellulose (Avicel ph101)	8 - 9.5
(c) Povidone K30	1 - 2
(d) Sucrose stearate (crodesta F150)	7 - 8
(e) Magnesium stearate NF	0.5 - 2.5
(f) Talc USP	0.5 - 5.0
(g) Titanium dioxide (USP)	0.15 - 0.3
(h) Hydroxypropylmethylcellulose 2910	0.3 - 0.6
(i) Polysorbate 80 (tween)	0.01 - 0.025
(j) Simeticone C emulsion USP (dry of 30%)	0.01 - 0.015
(k) a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester (dry of 30%)	7 - 11

*Cont  
E10*  
*D16  
cont* Purified water USP

0 (used for mixing).

*D17* 62. (Amended) A method of treatment of a patient's hypertension and/or angina comprising the administration of the preparation [of Diltiazem] of claim 56 to the patient in the evening for effective treatment of the patient's hypertension and/or angina the next morning.

*D18* [ Please add the following new claims. No new subject matter has been added. ]

*D18* 63. The preparation of claim 1, 2, 3 or 4 in capsule form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises a form of Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent.

64. The preparation of claim 1, 2, 3 or 4 in capsule form, wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent.

65. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a

central core containing the form of Diltiazem coated with a microporous membrane and the central core comprises a form of Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent.

D18  
CMT  
66. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of Diltiazem coated with a microporous membrane and the central core comprises a form of Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent.

67. The preparation of claim 1, 2, 3 or 4 in capsule form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of Diltiazem coated with a microporous membrane and the central core comprises a form of Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent, wherein the Diltiazem is mixed (in whole or in part) with the wetting agent.

68. The preparation of claim 1, 2, 3 or 4 in capsule form, wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core

comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent.

D18  
cont

69. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent wherein the Diltiazem is mixed (in whole or in part) with the wetting agent.

70. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent.

71. The preparation of claim 1, 2, 3 or 4 in capsule form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof



*Dilg*  
*cm*  
associated with a wetting agent, wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein.

72. The preparation of claim 1, 2, 3 or 4 in capsule form, wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein.

73. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of

the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein.

*Dig  
cm* 74. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein.

75. The preparation of claim 1, 2, 3 or 4 in capsule form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent, wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions

which the composition will meet therein wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation.

DLB  
CMT  
76. The preparation of claim 1, 2, 3 or 4 in capsule form, wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation.

77. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof

*Dis ant*  
associated with a wetting agent wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation.

78. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation.

79. The preparation of claim 1, 2, 3 or 4 in capsule form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent, wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose.

80. The preparation of claim 1, 2, 3 or 4 in capsule form, wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the

*D18  
CMT*

composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose.

81. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose.

82. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof

*D18  
amt*

associated with a wetting agent wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose.

83. The preparation of claim 1, 2, 3 or 4 in capsule form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent, wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid

causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside).

*Dis  
cont*

84. The preparation of claim 1, 2, 3 or 4 in capsule form, wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration



gradient through the membrane (high concentration inside and low concentration outside).

Dil  
Cmt

85. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside).

86. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active

*D18  
cont*

per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside).

87. The preparation of claim 1, 2, 3 or 4 in capsule form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent, wherein the Diltiazem is mixed (in whole or in

D/8  
cm

part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 120 mg of Diltiazem.

88. The preparation of claim 1, 2, 3 or 4 in capsule form, wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the

*Dil  
cont*

composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 120 mg of Diltiazem.

89. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the

*D18/*  
*cmf*

membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 120 mg of Diltiazem.

90. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from

a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 120 mg of Diltiazem.

D18  
cm

91. The preparation of claim 1, 2, 3 or 4 in capsule form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent, wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein wherein the membrane comprises a water-dispersible or water-soluble polymer and a water- acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 180 mg of Diltiazem.

92. The preparation of claim 1, 2, 3 or 4 in capsule form, wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active

*D18 cont*

per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 180 mg of Diltiazem.

93. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent wherein the Diltiazem is mixed (in whole or in part)

*D18  
CMT*

with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the Diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 180 mg of Diltiazem.

94. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of Diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the



*Dil  
cont*

composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 180 mg of Diltiazem.

95. The preparation of claim 1, 2, 3 or 4 in capsule form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent, wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane

*D/18  
cm*

hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 240 mg of Diltiazem.

96. The preparation of claim 1, 2, 3 or 4 in capsule form, wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration

gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 240 mg of Diltiazem.

D18  
cm

97. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 240 mg of Diltiazem.

98. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active

*Dil  
cont*

per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 240 mg of Diltiazem.

99. The preparation of claim 1, 2, 3 or 4 in capsule form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent, wherein the Diltiazem is mixed (in whole or in

Dis  
cont

part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 300 mg of Diltiazem.

100. The preparation of claim 1, 2, 3 or 4 in capsule form, wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the

*D18  
cont*

composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 300 mg of Diltiazem.

101. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the

membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 300 mg of Diltiazem.

D18  
Cmt

102. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from

a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 300 mg of Diltiazem.

103. *Dis Cont* The preparation of claim 1, 2, 3 or 4 in capsule form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent, wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 360 mg of Diltiazem.

104. The preparation of claim 1, 2, 3 or 4 in capsule form, wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active



*Dil  
cont*

per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 360 mg of Diltiazem.

105. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent wherein the Diltiazem is mixed (in whole or in part)

*Dil  
cont*

with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 360 mg of Diltiazem.

106. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the

*D18  
Cmt*

composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 360 mg of Diltiazem.

107. The preparation of claim 1, 2, 3 or 4 in capsule form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent, wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the

*Dis  
cont*

membrane hydrates the core within the membrane/ which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 420 mg of Diltiazem.

108. The preparation of claim 1, 2, 3 or 4 in capsule form, wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from

a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 420 mg of Diltiazem.

109. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 420 mg of Diltiazem.

110. The preparation of claim 1, 2, 3 or 4 in tablet form wherein the preparation releases the Diltiazem at a rate of less than about 15% of the total amount of active

*Dilg*  
*cont*

per hour during dissolution, and wherein the preparation is a diffusion controlled preparation and wherein each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent and wherein the Diltiazem is mixed (in whole or in part) with the wetting agent wherein the wetting agent assists to maintain the solubility of the Diltiazem in each bead, ensuring that the solubility of the Diltiazem is unaffected by the pH of the gastrointestinal tract or other adverse conditions which the composition will meet therein and wherein the membrane comprises a water-dispersible or water-soluble polymer and a water-, acid- and base-insoluble polymer of a neutral acrylic polymer including a neutral copolymer of acrylic acid ethyl ester and acrylic acid methyl ester which hydrates the preparation wherein the membrane further comprises hydroxypropylmethylcellulose and wherein the membrane hydrates the core within the membrane which when put in gastrointestinal fluid causes the membrane to swell while fluid penetrates and hydrates the bead, and dissolves the diltiazem and wetting agent and benefits from a concentration gradient through the membrane (high concentration inside and low concentration outside) wherein the preparation contains 420 mg of Diltiazem.

#### REMARKS

Claims 1 to 110 remain in the application. The fee for adding the new claims of \$864.00 USD is enclosed. If there should be any overpayment or underpayment of fees with respect to the additional claims, Applicant authorizes the Commissioner